Business context and reporting period
Registrant: The supplied filing is Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), not Decoy Therapeutics Inc. It is a Form 10-Q for the quarter ended March 31, 2023; financial statements are unaudited. Salarius is a clinical-stage biotechnology company developing seclidemstat (SP-2577), a targeted protein inhibitor, and SP-3164, a targeted protein degrader. It has no approved products and no product-sales revenue.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $3.73 million | $4.44 million |
| General and administrative | $1.70 million | $1.68 million |
| Operating expenses | $5.42 million | $6.12 million |
| Net loss | $5.34 million | $6.11 million |
| Basic and diluted loss per share | $2.23 | $3.30 |
| Net cash used in operations | $3.17 million | $3.52 million |
Interest income and other was $79,890, compared with $8,004. No meaningful profit margin is available because the company had no revenue and recorded a net loss. Cash and cash equivalents were $9.27 million at March 31, down from $12.11 million at year-end. Working capital was $5.4 million. Current liabilities were $4.50 million, primarily accounts payable ($3.51 million) and accrued liabilities ($0.99 million). The balance sheet lists no debt; the filing text does not provide a clear value for any debt balance.
Material changes versus the prior comparable period
Net loss improved by $0.77 million year over year, mainly as R&D expense fell $0.71 million, primarily due to lower SP-2577 spending. G&A was essentially flat. Operating cash use declined by about $0.35 million; the company also received $1.5 million from CPRIT during the quarter. Q1 2022 included $1.5 million of investing cash outflow for SP-3164 acquisition costs, while Q1 2023 had no investing cash outflow. Financing provided $0.34 million in Q1 2023 from ATM share sales, versus none in Q1 2022.
Outlook, risks and notable items
Management said March 31 cash was expected to fund operations only through the third quarter of 2023. The filing states that recurring losses and limited cash raise substantial doubt about the company’s ability to continue as a going concern; additional capital is required, and there is no assurance it can be obtained. Management anticipates ongoing losses and significant expenses. Equity financing could dilute shareholders; inability to raise funds could force delays, reductions or discontinuation of development.
FDA notified the company on May 5, 2023, after quarter-end, that the partial clinical hold on the seclidemstat Phase 1/2 trial had been resolved and the trial may resume. The enrollment pause followed a patient death classified as a suspected unexpected serious adverse reaction. SP-3164 remained in IND-enabling studies; management planned to submit an IND in the first half of 2023. From April 4 to May 11, the company sold 527,672 additional ATM shares for approximately $1.3 million gross proceeds. CPRIT grant support is subject to contract terms, including revenue-sharing obligations if covered products generate sales. No material legal proceedings were reported. Disclosure controls were judged effective at a reasonable-assurance level.
Important facts for investors to verify
- Confirm the filing is for Salarius Pharmaceuticals, Inc., not the company named in the request.
- Check subsequent financing and cash runway, including the ATM sales after March 31 and potential dilution.
- Track whether seclidemstat enrollment resumed and review subsequent clinical safety and efficacy updates.
- Verify whether SP-3164’s planned IND submission occurred and the resulting development timeline.
- Review CPRIT grant conditions and the filing’s going-concern warning when assessing funding risk.